

Kazuya Maeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6785729/publications.pdf>

Version: 2024-02-01

142
papers

8,189
citations

43973

48
h-index

49773

87
g-index

152
all docs

152
docs citations

152
times ranked

4153
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in in vitro models to predict the impact of efflux transporters in the small intestine and blood-brain barrier. <i>Journal of Pharmacological Sciences</i> , 2022, 148, 142-151.	1.1	7
2	Usefulness of Human Jejunal Spheroid-Derived Differentiated Intestinal Epithelial Cells for the Prediction of Intestinal Drug Absorption in Humans. <i>Drug Metabolism and Disposition</i> , 2022, 50, 204-213.	1.7	11
3	Clinical evaluation of [¹⁸ F]pitavastatin for quantitative analysis of hepatobiliary transporter activity. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 44, 100449.	1.1	3
4	Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1315-1323.	2.3	16
5	Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. <i>Clinical and Translational Science</i> , 2022, 15, 1519-1531.	1.5	13
6	⁶⁴ Cu-labeling of small extracellular vesicle surfaces via a cross-bridged macrocyclic chelator for pharmacokinetic study by positron emission tomography imaging. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121968.	2.6	8
7	Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 37, 100358.	1.1	19
8	Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum. <i>Drug Metabolism and Disposition</i> , 2021, 49, 84-93.	1.7	21
9	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 376-387.	1.6	8
10	Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies. <i>Stem Cell Reports</i> , 2021, 16, 295-308.	2.3	18
11	Prospect of in vitro Bile Fluids Collection in Improving Cell-Based Assay of Liver Function. <i>Frontiers in Toxicology</i> , 2021, 3, 657432.	1.6	0
12	Usability of Polydimethylsiloxane-Based Microfluidic Devices in Pharmaceutical Research Using Human Hepatocytes. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 3648-3657.	2.6	23
13	Classification of drugs for evaluating drug interaction in drug development and clinical management. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 41, 100414.	1.1	12
14	Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 76-88.	1.1	6
15	Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. <i>AAPS Journal</i> , 2020, 22, 133.	2.2	4
16	Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel. <i>Drug Metabolism and Disposition</i> , 2020, 48, 387-394.	1.7	23
17	Determination of the Kinetic Parameters for ¹²³ I Uptake by the Thyroid, Thyroid Weights, and Thyroid Volumes in Present-day Healthy Japanese Volunteers. <i>Health Physics</i> , 2020, 118, 417-426.	0.3	7
18	Practical Synthesis of [¹⁸ F]Pitavastatin and Evaluation of Hepatobiliary Transport Activity in Rats by Positron Emission Tomography. <i>Molecular Pharmaceutics</i> , 2020, 17, 1884-1898.	2.3	1

#	ARTICLE	IF	CITATIONS
19	Evaluation of transporter-mediated hepatobiliary transport of newly developed ¹⁸ F-labeled pitavastatin derivative, PTV-F1, in rats by PET imaging. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 317-324.	1.1	2
20	Elucidation of ¹ -methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1270-1280.	1.7	25
21	Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 387-395.	1.1	8
22	Quantitative investigation of hepatobiliary transport of [¹¹ C]telmisartan in humans by PET imaging. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 293-299.	1.1	13
23	Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 78-86.	1.1	51
24	Investigation of non-linear MATE1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 87-94.	1.1	8
25	Organic Anion Transporting Polypeptide 1a4 is Responsible for the Hepatic Uptake of Cardiac Glycosides in Mice. <i>Drug Metabolism and Disposition</i> , 2018, 46, 652-657.	1.7	11
26	A Clinical Quantitative Evaluation of Hepatobiliary Transport of [¹¹ C]Dehydropravastatin in Humans Using Positron Emission Tomography. <i>Drug Metabolism and Disposition</i> , 2018, 46, 719-728.	1.7	49
27	Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 125, 181-192.	1.9	17
28	PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 739-747.	1.3	51
29	Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1805-1816.	1.7	6
30	Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. <i>Molecular Pharmaceutics</i> , 2018, 15, 2277-2288.	2.3	32
31	Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers. <i>Pharmaceutical Research</i> , 2018, 35, 138.	1.7	69
32	In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines. <i>Pharmaceutical Research</i> , 2018, 35, 197.	1.7	10
33	Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2678-2687.	1.6	43
34	Possible Role of Organic Cation Transporters in the Distribution of [¹¹ C]Sulpiride, a Dopamine D ₂ Receptor Antagonist. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2558-2565.	1.6	20
35	Is Ethnic Variability in the Exposure to Rosuvastatin Explained Only by Genetic Polymorphisms in OATP1B1 and BCRP or Should the Contribution of Intrinsic Ethnic Differences in OATP1B1 Be Considered?. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2227-2230.	1.6	10
36	Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. <i>Drug Metabolism and Disposition</i> , 2017, 45, 779-789.	1.7	41

#	ARTICLE	IF	CITATIONS
37	A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2017, 34, 1570-1583.	1.7	34
38	Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2542-2550.	1.6	30
39	Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2739-2750.	1.6	14
40	Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. <i>Pharmaceutical Research</i> , 2017, 34, 1601-1614.	1.7	57
41	Prediction of drug interactions at transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, S4.	1.1	0
42	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2688-2694.	1.6	43
43	A microsensing system for the in vivo real-time detection of local drug kinetics. <i>Nature Biomedical Engineering</i> , 2017, 1, 654-666.	11.6	68
44	Determination of kinetic parameters for ¹²³ I thyroid uptake in healthy Japanese. <i>EPJ Web of Conferences</i> , 2017, 153, 08007.	0.1	1
45	Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 513-523.	2.3	81
46	Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (F _a) and Intestinal Availability (F _g): Effect of P-glycoprotein and CYP3A on F _a and F _g . <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 431-442.	1.6	9
47	Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1622-1632.	1.7	41
48	Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1925-1933.	1.7	55
49	The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1808-1818.	1.7	36
50	Radiosynthesis of novel pitavastatin derivative (¹⁸ F]PTV-1) as a tracer for hepatic OATP using a one-pot synthetic procedure. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 565-575.	0.5	5
51	Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2222-2230.	1.6	13
52	Usefulness of A Model-Based Approach for Estimating In-Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 891-896.	1.6	11
53	Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays. <i>Molecular Pharmaceutics</i> , 2016, 13, 438-448.	2.3	44
54	Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 as Important Regulators of the Pharmacokinetics of Substrate Drugs. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 155-168.	0.6	114

#	ARTICLE	IF	CITATIONS
55	Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2015, 43, 235-247.	1.7	125
56	Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 221-226.	1.1	21
57	Quantitative Analysis of the ABCG2 c.421C > A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3039-3048.	1.6	18
58	The role of breast cancer resistance protein (Bcrp/Abcg2) in triptolide-induced testis toxicity. <i>Toxicology Research</i> , 2015, 4, 1260-1268.	0.9	8
59	Involvement of Organic Cation Transporters in the Clearance and Milk Secretion of Thiamine in Mice. <i>Pharmaceutical Research</i> , 2015, 32, 2192-2204.	1.7	22
60	A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 793-801.	1.1	12
61	The synthesis of [¹⁸ F]pitavastatin as a tracer for hOATP using the Suzuki coupling. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 1113-1121.	1.5	19
62	Integrative analysis of transporter-mediated drug-drug interactions. <i>Drug Delivery System</i> , 2014, 29, 426-438.	0.0	0
63	⁶ -Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2014, 42, 685-694.	1.7	47
64	In Silico Prediction of Major Drug Clearance Pathways by Support Vector Machines with Feature-Selected Descriptors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1811-1819.	1.7	24
65	Naphthalene-hydrophobized β -1,3-glucan nanogel for doxorubicin delivery to immunocytes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1880-1883.	1.0	5
66	Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 59, 94-103.	1.9	78
67	Direct and Rapid Genotyping of SLCO1B1 388A>G and 521T>C in Human Blood Specimens Using the SmartAmp-2 Method. <i>AAPS Journal</i> , 2013, 15, 618-622.	2.2	2
68	Transporter biology in drug approval: Regulatory aspects. <i>Molecular Aspects of Medicine</i> , 2013, 34, 711-718.	2.7	41
69	Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 37-51.	2.3	76
70	Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. <i>BMC Systems Biology</i> , 2013, 7, S3.	3.0	24
71	Automated Extraction of Information on Chemical-P-glycoprotein Interactions from the Literature. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2506-2510.	2.5	2
72	Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 581-612.	4.2	111

#	ARTICLE	IF	CITATIONS
73	Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 45-78.	1.1	345
74	Microdose pharmacogenetic study of 14C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9 [∗] 3 on its pharmacokinetics and metabolism. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 642-648.	1.9	12
75	Investigation of the Effect of the Uneven Distribution of CYP3A4 and P-Glycoprotein in the Intestine on the Barrier Function against Xenobiotics: A Simulation Study. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3196-3204.	1.6	14
76	Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17 β -Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1859-1866.	1.7	84
77	Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 654-661.	1.0	30
78	Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [¹¹ C]Dehydropravastatin in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 193-202.	1.3	51
79	Studies on the Intestinal Absorption Characteristics of Sulfasalazine a Breast Cancer Resistance Protein (BCRP) Substrate. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 71-74.	1.1	11
80	Cost-effectiveness Analysis of Microdose Clinical Trials in Drug Development. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 187-195.	1.1	18
81	Prediction of Hepatic Transporter-Mediated Drug-Drug Interaction from In Vitro Data. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 121-153.	0.2	3
82	In Vivo Biliary Clearance Should Be Predicted by Intrinsic Biliary Clearance in Sandwich-Cultured Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2012, 40, 602-609.	1.7	41
83	Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1078-1089.	1.0	91
84	Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes. <i>Molecular Pharmaceutics</i> , 2012, 9, 3535-3542.	2.3	94
85	Expression and Transport Function of Drug Uptake Transporters in Differentiated HepaRG Cells. <i>Molecular Pharmaceutics</i> , 2012, 9, 3434-3441.	2.3	45
86	Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an <i>in vivo</i> inhibitor of BCRP. <i>British Journal of Pharmacology</i> , 2012, 166, 1793-1803.	2.7	118
87	Whole-body distribution and radiation dosimetry of [¹¹ C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. <i>Nuclear Medicine and Biology</i> , 2012, 39, 847-853.	0.3	46
88	Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 1053-1064.	2.3	144
89	PET Imaging-Based Evaluation of Hepatobiliary Transport in Humans with (15R)- ¹¹ C-TIC-Me. <i>Journal of Nuclear Medicine</i> , 2012, 53, 741-748.	2.8	101
90	Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 344-354.	0.7	15

#	ARTICLE	IF	CITATIONS
91	Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 689-700.	0.3	18
92	S13-1. Clinical Examples of Transporter-Mediated Drug-Drug Interactions and Their Evaluation Methods. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 43, 253-254.	0.1	0
93	Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 263-270.	2.3	44
94	Critical Role of Organic Anion Transporters 1 and 3 in Kidney Accumulation and Toxicity of Aristolochic Acid I. <i>Molecular Pharmaceutics</i> , 2011, 8, 2183-2192.	2.3	67
95	The Involvement of Organic Anion Transporting Polypeptide in the Hepatic Uptake of Telmisartan in Rats: PET Studies with [¹¹ C]Telmisartan. <i>Molecular Pharmaceutics</i> , 2011, 8, 1789-1798.	2.3	52
96	The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 523-530.	0.7	54
97	Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 495-505.	0.7	44
98	Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 575-581.	2.3	192
99	Novel strategies for microdose studies using non-radiolabeled compounds. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 532-538.	6.6	47
100	Clinical Relevance of Liquid Chromatography Tandem Mass Spectrometry as an Analytical Method in Microdose Clinical Studies. <i>Pharmaceutical Research</i> , 2011, 28, 1963-1972.	1.7	19
101	Involvement of Different Human Glutathione Transferase Isoforms in the Glutathione Conjugation of Reactive Metabolites of Troglitazone. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2290-2297.	1.7	26
102	Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1031-1038.	1.7	87
103	Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1503-1510.	1.7	71
104	Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2361-2369.	1.7	22
105	Chapter 22. Impact of Drug Transporters in the Pharmacological and Adverse Reactions of Drugs. <i>RSC Drug Discovery Series</i> , 2011, , 563-598.	0.2	1
106	DNA Methylation Profiles of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines. <i>Pharmaceutical Research</i> , 2010, 27, 510-516.	1.7	36
107	Positron Emission Tomography Studies Using (15 <i>R</i>)-16 <i>m</i> -[¹¹ C]tolyl-17,18,19,20-tetranorisocarbacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 314-323.	1.3	45
108	Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans. <i>Drug Metabolism and Disposition</i> , 2010, 38, 215-222.	1.7	182

#	ARTICLE	IF	CITATIONS
109	In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters. Drug Metabolism and Disposition, 2010, 38, 1362-1370.	1.7	35
110	Web-Based Database as a Tool to Examine Drug-Drug Interactions Involving Transporters. , 2010, , 387-412.		2
111	The Use of Hepatocytes to Investigate Drug Uptake Transporters. Methods in Molecular Biology, 2010, 640, 327-353.	0.4	30
112	Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments. Drug Metabolism and Disposition, 2009, 37, 1471-1479.	1.7	72
113	The Eighth and Ninth Transmembrane Domains in Organic Anion Transporting Polypeptide 1B1 Affect the Transport Kinetics of Estrone-3-Sulfate and Estradiol-17 β -D-glucuronide. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 551-557.	1.3	48
114	The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine. Drug Metabolism and Disposition, 2009, 37, 555-559.	1.7	97
115	Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data. Pharmaceutical Research, 2009, 26, 822-835.	1.7	37
116	Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 652-662.	1.3	333
117	Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on <i>SLCO1B1</i> and <i>ABCC2</i> Polymorphisms. Journal of Clinical Pharmacology, 2009, 49, 1309-1317.	1.0	20
118	5. Microdose Clinical Study for Drug Development. Japanese Journal of Clinical Pharmacology and Therapeutics, 2009, 41, 27-34.	0.1	1
119	Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 617-628.	1.4	34
120	Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine. Molecular Pharmacology, 2008, 73, 1474-1483.	1.0	83
121	Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin. Drug Metabolism and Disposition, 2008, 36, 2014-2023.	1.7	322
122	Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide. Drug Metabolism and Disposition, 2008, 36, 796-805.	1.7	78
123	Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans. Drug Metabolism and Disposition, 2008, 36, 663-669.	1.7	78
124	Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs. Drug Metabolism and Pharmacokinetics, 2008, 23, 223-235.	1.1	139
125	Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor. Drug Metabolism and Disposition, 2007, 35, 2166-2176.	1.7	122

#	ARTICLE	IF	CITATIONS
127	SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 541-547.	2.3	147
128	Uptake of Ursodeoxycholate and Its Conjugates by Human Hepatocytes: Role of Na ⁺ -Taurocholate Cotransporting Polypeptide (NTCP), Organic Anion Transporting Polypeptide (OATP) 1B1 (OATP-C), and OATP1B3 (OATP8). <i>Molecular Pharmaceutics</i> , 2006, 3, 70-77.	2.3	68
129	Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 427-439.	2.3	173
130	DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1229-1236.	1.7	280
131	PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1109-1115.	1.7	164
132	INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID. <i>Drug Metabolism and Disposition</i> , 2006, 34, 743-747.	1.7	68
133	INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1247-1254.	1.7	190
134	Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance-Associated Protein 2 Using Ligand-Based Drug Design Techniques. <i>Pharmaceutical Research</i> , 2005, 22, 260-269.	1.7	42
135	CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1477-1481.	1.7	176
136	Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1059-1067.	1.3	189
137	Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin. <i>Molecular Pharmacology</i> , 2005, 68, 800-807.	1.0	242
138	Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 876-882.	1.3	167
139	Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 139-146.	1.3	427
140	Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs. <i>Pharmaceutical Research</i> , 2004, 21, 2133-2134.	1.7	51
141	pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. <i>Journal of Controlled Release</i> , 2002, 82, 71-82.	4.8	28
142	In Vitro–In Vivo Scale-up of Drug Transport Activities. , 0, , 557-588.		9